Prenylated Flavonoids with Selective Toxicity against Human Cancers

Int J Mol Sci. 2023 Apr 18;24(8):7408. doi: 10.3390/ijms24087408.

Abstract

The antiproliferative activity of xanthohumol (1), a major prenylated chalcone naturally occurring in hops, and its aurone type derivative (Z)-6,4'-dihydroxy-4-methoxy-7-prenylaurone (2) were investigated. Both flavonoids, as well as cisplatin as a reference anticancer drug, were tested in vivo against ten human cancer cell lines (breast cancer (MCF-7, SK-BR-3, T47D), colon cancer (HT-29, LoVo, LoVo/Dx), prostate cancer (PC-3, Du145), lung cancer (A549) and leukemia (MV-4-11) and two normal cell lines (human lung microvascular endothelial (HLMEC)) and murine embryonic fibroblasts (BALB/3T3). Chalcone 1 and aurone 2 demonstrated potent to moderate anticancer activity against nine tested cancer cell lines (including drug-resistant ones). The antiproliferative activity of all the tested compounds against cancer and the normal cell lines was compared to determine their selectivity of action. Prenylated flavonoids, especially the semisynthetic derivative of xanthohumol (1), aurone 2, were found as selective antiproliferative agents in most of the used cancer cell lines, whereas the reference drug, cisplatin, acted non-selectively. Our findings suggest that the tested flavonoids can be considered strong potential candidates for further studies in the search for effective anticancer drugs.

Keywords: anticancer selectivity; antiproliferative activity; aurone; human carcinoma; xanthohumol.

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Cell Line, Tumor
  • Cell Proliferation
  • Chalcones* / pharmacology
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use
  • Female
  • Flavonoids / pharmacology
  • Flavonoids / therapeutic use
  • Humans
  • Mice

Substances

  • xanthohumol
  • Cisplatin
  • Chalcones
  • Flavonoids
  • Antineoplastic Agents

Grants and funding

The APC is financed by Wrocław University of Environmental and Life Sciences.